Purpose: This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC).
Introduction
Several fluorouracil-based chemotherapy regimens have been successfully developed for patients with metastatic colorectal cancer (mCRC). Incremental improvements in response rates, progression-free survival (PFS), and overall survival have been observed with fluorouracil in combination with leucovorin and oxaliplatin (FOLFOX), leucovorin and irinotecan (FOLFIRI), and leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI). Nonetheless, survival remains limited with a 5-year rate of less than 8% (1) . Strategies to further improve outcomes have focused on adding targeted therapies to established regimens.
Advances in our understanding of the molecular basis of cancer proliferation, angiogenesis, and metastasis enabled the development of therapies that target signaling pathways associated with cellular differentiation, proliferation, and survival. Among these, EGF and VEGF are key targets (1) . The addition of monoclonal antibodies (mAbs) that target tyrosine kinase activity (ligands or receptors) to mCRC chemotherapy regimens improved clinical outcomes with acceptable toxicity. These include bevacizumab (inhibits VEGF; refs. [2] [3] [4] [5] , and the EGF receptor (EGFR) inhibitors cetuximab and panitumumab (6) (7) (8) (9) . Nonetheless, response can be absent if the target is not a disease driver, and resistance can be present at the start of treatment or can emerge when tumor or stromal cells switch to alternative pathways. The constitutive KRAS and BRAF mutations confer resistance to cetuximab and panitumumab, and KRAS is now a valid biomarker for cetuximab and panitumumab (10) . Approximately 40% of patients with CRC have a KRAS mutation, meaning a significant proportion will not be eligible for EGFR inhibitors (10) .
Targeting a broader spectrum of molecules involved in CRC cell proliferation and death, such as receptor and intracellular tyrosine kinases, may confer anticancer activity with less risk of resistance (11) . Sorafenib is an oral multikinase inhibitor that targets intracellular kinases (CRAF, BRAF, mutant BRAF), as well as cell surface receptor kinases, including platelet-derived growth factor receptor (PDGFR), VEGFR-1-3, stem cell factor receptor (KIT), and Feline McDonough Sarcoma (FMS)-related tyrosine kinase 3 (FLT3; refs. 12 and 13). Clinical efficacy and tolerability of sorafenib have been shown in renal cell carcinoma (14) and hepatocellular carcinoma (15, 16) . Preclinical evidence indicates the primary target of sorafenib in renal cell carcinoma is angiogenesis via VEGFR, whereas in hepatocellular carcinoma, cell proliferation, and survival are targeted via the RAF/MEK/ERK pathway, and angiogenesis via VEGFR and PDGFR (12, 17, 18) .
Preclinical studies also showed the activity of sorafenib against colon cancer cells, but also indicated differential targeting of cell proliferation and/or angiogenesis by tumor model (12, (19) (20) (21) . Early clinical studies showed the feasibility of combining sorafenib with chemotherapies used in mCRC, such as irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin, with encouraging activity in solid tumors including mCRC (22) (23) (24) . In a phase I study of 37 patients with advanced solid tumors, 7/9 patients with CRC treated with oxaliplatin (130 mg/m 2 on Day 1 of a 3-week cycle) and the standard sorafenib dose (400 mg b.i.d. continuously) achieved stable disease for at least 6 weeks (23).
Here we present results from a phase IIb, double-blind, placebo-controlled, randomized trial that assessed the addition of sorafenib to first-line modified FOLFOX6 (mFOL-FOX6) in patients with mCRC. The standard sorafenib regimen (400 mg b.i.d. continuously) was used based on the collective results from the phase I combination studies (22) (23) (24) as well as its proven benefit in other difficult-totreat adenocarcinomas (14) (15) (16) . Modified FOLFOX6 was chosen because it was the most commonly used FOLFOX regimen across the various centers and countries of this international study. The objective was to determine whether efficacy and tolerability results would support a phase III confirmatory trial.
Patients and Methods

Patients
Eligible patients were 18 years old, with histologically confirmed, measurable metastatic adenocarcinoma of the colon or rectum (stage IV; ref. 25) , and an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. Prior radiotherapy was allowed, but at least 1 measurable, nonirradiated, metastatic lesion was required, as was a tumor tissue sample for analysis of KRAS and BRAF mutations. Patients who had received prior chemotherapy for metastatic disease were not eligible, nor were patients with brain metastases, active cardiac disease, or serious bone marrow, liver, or renal dysfunction. Patients who had received adjuvant treatment for CRC, including a FOLFOX regimen, were eligible provided that they had completed treatment at least 12 months before randomization. The protocol was approved by the independent ethics committees/institutional review boards of all participating sites or countries. The trial was conducted according to Good Clinical Practice Guidelines and in accordance with the Declaration of Helsinki. All patients provided written informed consent. The study is registered at ClinicalTrials.gov (NCT00865709).
Study design
This was a phase IIb, randomized, double-blind trial conducted at centers in Belgium, Romania, Russia, Spain, the United Kingdom, and the United States. Patients were stratified by radiologic evidence of liver involvement and number of metastatic sites (<3 or 3) and randomly assigned (1:1) to mFOLFOX6 plus sorafenib or matching placebo.
Treatment
The mFOLFOX6 regimen was administered every 14 days and consisted of oxaliplatin, levo-leucovorin (or leucovorin
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Study endpoints
The primary endpoint was PFS. Secondary endpoints included overall survival, time to progression (TTP), overall response rate (ORR), duration of response (DOR), safety, and tolerability. Tumor response was investigator assessed and evaluated radiologically at baseline and every 8 weeks using Response Evaluation Criteria in Solid Tumors (RECIST; ref. 26) . Active follow-up was extended to patients who discontinued treatment without disease progression. Adverse events were graded using Common Terminology Criteria for Adverse Events (version 3.0). Serious adverse events (SAEs) included events that resulted in death, were life-threatening, required or extended hospitalization, or resulted in persistent or significant disability.
Statistical analyses
Analysis of PFS was based on the log-rank test. Based on historical data, the expected PFS in the control arm was 8 months (4). A sample size of 120 events would provide >85% power with a 2-sided a ¼ 0.20, assuming a target HR of 0.65 between sorafenib and placebo. The target study population was 180 patients. Analysis of overall survival was planned after 120 deaths.
Time-to-event endpoints were analyzed by the KaplanMeier method in the intent-to-treat (ITT) population. For PFS, patients without documentation of progression or death at the time of analysis were censored at final tumor assessment or postrandomization visit; patients who initiated nonstudy cancer treatment and were without disease progression were censored at last tumor assessment before the start of the new treatment; patients with no postbaseline tumor assessment were censored at Day 1; and patients who experienced progressive disease or death 18 weeks or longer from the last tumor assessment were censored at the last tumor assessment. A stratified log-rank test with the randomization stratification factors as covariates was used to compare treatment arms, and the relative risk for sorafenib versus placebo was estimated with a stratified Cox regression model.
Secondary analyses of PFS included a per-protocol analysis (patients with no major protocol violations), and a nonstratified analysis. Planned subgroup analyses of PFS and overall survival were done using the Kaplan-Meier method and a nonstratified Cox regression for subgroups defined by baseline factors of liver involvement (yes or no), number of metastatic sites (<3 or 3), region (East or West), KRAS status (wild-type or mutant), and BRAF status (wildtype or mutant). KRAS and BRAF mutant status was determined by allelic discrimination (Supplementary Appendix) and centrally evaluated at University Hospital Gasthuisberg, Leuven, Belgium (S.T.). Exploratory analyses of PFS and overall survival were done for subgroups defined by NRAS and PIK3CA status (wild-type or mutant), age (<65 or 65 years), gender, ECOG performance status (0 or 1), disease stage at diagnosis (I-III or IV), and months since initial diagnosis (<2 or 2). ORR was compared between groups using the Cochran-Mantel-Haenszel test, adjusting for the stratification factors. Descriptive statistics summarized safety and tolerability variables, including study drug exposure and adverse events rates. Statistical analyses were done with SAS version 9.1 or later (SAS Institute). The lead author (J. T.) had full access to study data and analyses, which were available to all authors upon request.
Results
Patient recruitment occurred between March 2009 and February 2010 with 198 patients randomized (Fig. 1) . Data cut-off for the primary analysis of PFS, response, safety, and tolerability was January 31, 2011. An analysis of overall survival was subsequently conducted after 123 deaths with a cut-off date of December 1, 2011, and a median follow-up of 22.4 months.
Baseline characteristics were generally balanced between treatment arms (Table 1) . Most patients had an ECOG performance status of 1 (64.6%), stage IV disease as initial diagnosis (68.2%), <3 metastatic sites (71.7%), and liver involvement (80.8%). Of note, the sorafenib arm had fewer males compared with the placebo arm (43.3% vs. 62.4%), less exposure to adjuvant chemotherapy (7.2% vs. 12.9%), and lower rates of KRAS mutations (37.1% vs. 48.5%). BRAF mutations were infrequent in both arms (3.1% vs. 5.0%).
Efficacy outcomes
Median PFS was 9.1 months for the sorafenib arm and 8.7 months for the placebo arm [HR ¼ 0.88; 95% confidence interval (CI), 0.64-1.23; P ¼ 0.46; Fig. 2] . Similar results were observed in the prespecified subgroup analyses (Table  2 ). In patients with wild-type KRAS, the median PFS was 9.5 months versus 9.2 months, respectively (HR ¼ 0.84; 95% CI, 0.52-1.36), with corresponding medians of 7.8 months versus 7.6 months, respectively, in the mutant KRAS subgroup (HR ¼ 0.96; 95% CI, 0.59-1.58). In patients with wild-type BRAF, the median PFS was 9.2 months versus 9.0 months, respectively (HR ¼ 0.91; 95% CI, 0.64-1.29), and the median PFS for mutant BRAF was 8.6 months versus 7.3 months, respectively (HR ¼ 0.89; 95% CI, 0.15-5.42).
Median overall survival was 17.6 months in the sorafenib arm and 18.1 months in the placebo arm (HR ¼ 1.13; 95% CI, 0.79-1.61; P ¼ 0.51). In patients with wild-type KRAS, median overall survival was 19.9 months versus 16.8 months, respectively (HR ¼ 0.89; 95% CI, 0.54-1.48), and 17.0 months versus 19.4 months, respectively, in patients with mutant KRAS (HR ¼ 1.29; 95% CI, 0.74-2.24). In patients with wild-type BRAF, median overall survival was 18.8 months versus 18.3 months, respectively (HR ¼ 1.09; 95% CI, 0.74-1.60), and 13.9 months versus 11.9 months, respectively, in patients with mutant BRAF (HR ¼ 0.46; 95% CI, 0.09-2.39). Exploratory subgroup analyses showed slightly different outcomes between treatment arms by gender and ECOG status ( Table 2 ). There were no differences in survival outcomes between treatment arms in the PIK3CA or in the NRAS subgroups (Supplementary Appendix Tables SA1 and SA2) .
Median TTP was 9.2 months in the sorafenib arm and 9.0 months in the placebo arm (HR ¼ 0.83; 95% CI, 0.59-1.17), and the ORR was 46.4% and 60.4%, respectively (Table 3) . Partial response was lower in the sorafenib arm compared with mFOLFOX6 alone (44.3% vs. 59.4%), but the rate of stable disease was higher (40.2% vs. 30.7%). Complete response was achieved by 2 patients in the sorafenib arm and 1 patient in the placebo arm.
Safety and tolerability
Treatment-related adverse events occurring in 10% of patients are shown in Table 4 . The most common adverse events (any grade) in the sorafenib and placebo arms included neutropenia (62% vs. 38%), peripheral neuropathy (61% vs. 65%), diarrhea (48% vs. 35%), nausea (36% vs. 47%), HFSR (54% vs. 10%), and asthenia (28% vs. 19%). Other adverse events (any grade) of interest were stomatitis (22% vs. 4%), rash (23% vs. 9%), and hypertension (19% vs. 5%). The most common grade 3/4 adverse events in the sorafenib and placebo arms were neutropenia (48% vs. 22%), peripheral neuropathy (16% vs. 21%), and HFSR (20% vs. 0%). Treatment-related SAEs occurred in 21 (22%) patients in the sorafenib arm and 16 (16%) patients in the placebo arm. There were 2 treatment-related deaths in the sorafenib arm (1 pancytopenia and 1 renal failure) and 1 in the placebo arm (cardiovascular insufficiency).
More frequent dose interruptions and reductions were observed for sorafenib than placebo (Supplementary Appendix Table SA3 ). The average daily dose of sorafenib was lower than placebo (mean 553.1 mg vs. 728.1 mg), which corresponded to a greater frequency of dose reductions (66.0% vs. 27.7%) and a shorter mean duration of treatment (30.5 weeks vs. 33.7 weeks). Similar trends were observed for components of mFOLFOX6, although the magnitude of the difference between treatment arms was less pronounced. Overall, 9.4% of patients discontinued treatment because of adverse events in the sorafenib arm compared with 5.9% in the placebo arm.
Discussion
In this randomized phase IIb trial, the addition of sorafenib 400 mg b.i.d. to mFOLFOX6 compared with placebo did not show an improvement in PFS to support a phase III trial. Generally, there was no differential outcome across subgroups, including KRAS and BRAF subgroups. There was also no improvement in TTP or ORR. There were no unexpected toxicities associated with the addition of sorafenib, but there were increases in some grade 3/4 adverse event rates, most notably neutropenia and HFSR, which led to increased rates of dose modifications and treatment discontinuations for reasons other than disease progression. Overall, the average daily dose of sorafenib was lower than placebo, and exposure to each of the mFOLFOX6 components was also lower in the sorafenib arm.
Although these results allow us to exclude a strong therapeutic benefit with sorafenib plus mFOLFOX6, a number of factors may have influenced the results and should be considered. First, the sample size would have been too small to adequately assess a modest therapeutic benefit. Given the inter-and intrapatient heterogeneity in primary and metastatic CRC tumor types (27, 28) , a more modest benefit would not be unexpected for a targeted therapy. Second, use of sorafenib in mCRC may be better suited for regimens that are less active than mFOLFOX6 but more tolerable and where an increase in activity would be more easily detected. Third, the 400 mg b.i.d. dose of sorafenib may not have provided sufficient target inhibition, which may have been accentuated by the decrease in dose intensity of both sorafenib and mFOLFOX6 over the course of treatment.
Thus far, results of studies with targeted therapies in combination with mCRC chemotherapy have been mixed, ranging from significant improvements in PFS or overall survival to decreases in PFS or overall survival, depending on the chemotherapy regimen and patient population (2-5, 9, 29-31) . A number of phase III studies have shown that adding bevacizumab to fluorouracil-based regimens improves PFS with or without a corresponding improvement in overall survival (2) (3) (4) 29) , but the magnitude of the benefits have been inconsistent (5) . This may be related to the fluorouracil backbone combined with bevacizumab and/or the line of therapy (2-4). Variability in results has also been observed across cetuximab (6, 9, 31) and panitumumab studies (7, 8) . It has been hypothesized that inconsistencies in outcomes with mAbs could also be related to their high specificity, which may make them susceptible to resistance through redundant signaling pathways (11) . Attempts to broaden activity by combining different mAbs have not proven fruitful in mCRC (32) (33) (34) .
Results with small-molecule multikinase inhibitors with a broader spectrum of inhibitory targets than mAbs (35) have also been mixed, although limited data are available in addition to the results reported here (36) (37) (38) (39) (40) . In 2 phase III trials in mCRC, adding vatalanib (targets VEGFR1-3, PDGFRb, and KIT) to first-or second-line FOLFOX4 did not improve PFS or overall survival (36, 37) , and a phase III study of sunitinib (targets VEGFR1-3, PDGFRa/b, KIT, FLT3, CSF1R, RET) with FOLFIRI failed to show an improvement in the primary endpoint of PFS (41) . Cediranib (targets VEGFR1-3, PDGFRb, and KIT), has been evaluated with FOLFOX in mCRC in 3 different phase II/III trials (42) (43) (44) , with only 1 study demonstrating a statistically significant but clinically modest improvement in median PFS (þ0.4 months; ref. 45) . Nevertheless, other multikinase inhibitors may have potential in mCRC. In a phase III trial, regorafenib (targets VEGFR1-3, Tie-2, PDGFR, FGFR, KIT, RET, and BRAF) provided a survival benefit when added to best supportive care in patients with refractory mCRC (46, 47) . It is notable that regorafenib was active in the refractory setting as monotherapy, whereas mCRC studies with other targeted agents lacked single-agent activity or were paired with chemotherapy in the first-or second-line setting.
Several factors may explain the variability in results with targeted therapies in mCRC. It is becoming evident that the genetic profiles of tumors are predictive of treatment response to targeted therapies. In our study, by adding sorafenib to a standard first-line chemotherapy for mCRC, several pathways shown to be critical in mCRC were targeted, such as angiogenesis via extracellular tyrosine kinase receptors VEGFR1-3 and PDGFR, as well as downstream protein effectors of tyrosine kinase receptors (e.g., EGFR) including CRAF, BRAF, and mutant BRAF (12, 13, 20, 21) . As RAF is targeted by sorafenib and is downstream of RAS, we hypothesized that mCRC patients could potentially derive benefit by the addition of sorafenib independent of KRAS and BRAF gene mutation status. However, this is a highly redundant pathway with complex feedback loops, which makes it unlikely for RAF inhibition alone to be sufficient for antitumoral activity (48) .
In this study, the tumor sample was taken from either the primary or metastatic site, and it does not seem that KRAS or BRAF status had a significant impact on outcomes in patients receiving sorafenib. However, the size of the study population and subgroups limits the interpretation of these data. Sorafenib may be more active with other chemotherapy regimens and/or in more specific patient populations. Although a pharmacokinetic interaction between sorafenib and oxaliplatin was not detected in a phase I trial of solid tumors (23) , some preclinical evidence suggests that sorafenib may reduce cellular uptake of platinum compounds (49) . The addition of sorafenib to other mCRC regimens, such as irinotecan alone (50) or FOLFIRI (NCT00839111), are being explored. In addition, studies in various mCRC models showed differential response to sorafenib (12, 20, 21) . Sorafenib showed inhibition of tumor growth and angiogenesis in HT-29 colon cells (BRAF V600E mutation), inhibition of tumor growth in HCT-116 cells (activating KRAS mutation), but notably less activity in DLD-1 (activating KRAS mutation) and Colo-205 (BRAF V600E mutation) cells. Further assessment of sorafenib and other targeted therapies across mCRC models may help us to better understand and predict treatment response of primary and metastatic tumors in CRC patients.
In conclusion, the dose and schedule of sorafenib with first-line mFOLFOX6 in this study did not show a PFS benefit in patients with mCRC to support a phase III trial of similar design. KRAS and BRAF status did not seem to impact response to sorafenib, but patient numbers were small. Further assessment of tumor samples for biomarkers are ongoing and includes gene expression profiling. Although the results of this study do not support further development of sorafenib with this combination in an unselected patient population, they may help to guide the design of future clinical trials in mCRC with targeted therapies focusing on molecularly characterized populations.
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